Retatrutide 10 mg/vial – US Stock

Retatrutide 10 mg/vial from Hilma Biocare contains retatrutide (LY-3437943), a synthetic 39-amino-acid peptide designed to activate three metabolic hormone receptors: GLP-1R, GIPR, and the glucagon receptor (GCGR). The supplied product information identifies retatrutide as an investigational compound being studied in clinical research involving obesity and metabolic disease.

Product Overview

Retatrutide is a triple receptor agonist that combines activity at the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. According to the supplied information, the molecule is based on a GIP peptide backbone and is designed to resist cleavage by the DPP-4 enzyme.

The source material describes retatrutide as being investigated for weight management and glycemic control. Because the supplied information does not provide a dosage form beyond the stated vial presentation, no additional formulation or administration characteristics are added here.

Active Ingredient

The active compound is Retatrutide (LY-3437943).

Product Characteristics

The supplied information identifies retatrutide as:

• A 39-amino-acid peptide
• A triple receptor agonist
• Active at GLP-1R, GIPR, and GCGR
• Designed to resist DPP-4-mediated cleavage
• Supplied as a 10 mg/vial product
• Listed as US Stock

Product Specifications

Mechanism of Action

Retatrutide is designed to simultaneously activate three receptor pathways involved in metabolic regulation.

GLP-1 Receptor Activity

GLP-1 receptor activation is associated with physiological processes involved in appetite regulation, glucose metabolism, and insulin secretion. The supplied description links this activity to increased satiety and reduced appetite.

GIP Receptor Activity

GIP receptor activity contributes to the peptide’s multi-receptor pharmacology and is intended to complement GLP-1 receptor activity in the regulation of metabolic processes.

Glucagon Receptor Activity

Activation of the glucagon receptor provides the third component of retatrutide’s mechanism. The combined GLP-1, GIP, and glucagon receptor activity is being investigated for its effects on energy metabolism and body weight.

Clinical Research

The supplied source describes clinical research investigating retatrutide in adults with obesity or overweight and reports substantial body-weight reductions during clinical trials.

These figures should be understood as reported clinical-study findings rather than guaranteed individual outcomes. Clinical research results can vary according to study design, participant characteristics, treatment duration, and other factors.

Retatrutide remains an investigational compound, and research findings should not be presented as establishing a guaranteed treatment effect for an individual customer.

Important Information

Retatrutide is a biologically active investigational peptide. The information on this page is provided for product identification and general informational purposes and does not constitute personalized medical advice.

No dosing recommendations, injection instructions, treatment protocols, or weight-loss programs are provided. Individuals considering investigational compounds should consult an appropriately qualified healthcare professional and review current regulatory and clinical information.

About Hilma Biocare USA

Retatrutide 10 mg/vial is listed as part of the Hilma Biocare product range and is identified as US Stock. The product contains 10 mg of retatrutide (LY-3437943) per vial according to the supplied product information.